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Abstract
A genetic interruption of Bacillus subtilis 168's native nitric oxide synthase enzyme (bsNOS) is to
be created by inserting a gene for kanamycin resistance (KAN) into the center of the gene. To accomplish
this, a plasmid has been constructed (pUC19∆bsNOS) which includes the bsNOS gene separated into 5'
and 3' halves with a KAN gene from p34S between them. The plasmid vector was isolated by digesting
Escheria coli plasmid pUC19 with KpnI and PstI, and the KAN gene was cut from Escheria coli plasmid
p34S using XbaI. The 5' and 3' halves of the bsNOS gene were amplified using the polymerase chain
reaction with custom primers that imparted appropriate digestion sites to the ends of both amplified
fragments. The vector and bsNOS fragments were all produced and ligated into a preliminary plasmid
form (pNOS20) and amplified. This plasmid was subsequently digested with XbaI, and the KAN
fragment was ligated into place between the 5' and 3' XbaI sites. Knockout colonies were generated by
amplifying the desired insert from the pUC19∆bsNOS plasmid using PCR and then using it for
transforming competent wild-type Bacillus subtilis via electroporation. Potential Bacillus subtilis
∆bsNOS knockout colonies may have been generated but are pending confirmation.
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Chapter 1: Background
Nitric Oxide as a Biological Signal
Nitric oxide (NO) was first identified as a eukaryotic trans-cellular signaling molecule in 1987 (1)
and was later shown to be generated from L-arginine by an enzyme (Figure 1.1-A) known as nitric oxide
synthase (NOS) (2). Mammalian NOS enzymes have been found to perform functions ranging from
vasodilatation (3) to acting as a broad-spectrum antimicrobial during immune system responses (4).
Nitric oxide is effective as a broad spectrum antibiotic because of its high reactivity as a free
radical species and its lipophilic nature (5). It is a small, membrane-permeable molecule capable of
competitively binding precious metals, inhibiting enzymes, and generating oxidizing chemicals such as
nitric acid, peroxynitrite, or superoxide in solution which in turn damage DNA (5). In eukaryotes, nitric
oxide is generally produced at concentrations high enough to have these effects by inducible NOS (iNOS)
during macrophage attack. However, nitric oxide has also been shown to affect bacteria at concentrations
too low for toxic or acidifying effects (6), indicating more involved mechanisms at work.
Later efforts revealed prokaryotic NO-dependent pathways associated with denitrification and
anaerobic gene expression. Nitric oxide was shown to be an activator of transcription factors ResD and
ResE, key signals for anaerobic gene expression in Bacillus subtilis (Figure 1.1-B) and other microbes.
While they were known at the time to be activated under low-oxygen conditions, it was discovered that
full activation also required elevated concentrations of NO (7-9). This mechanism suggested that many
bacteria have evolved to detect NO as an indication of impending oxidative stressors, such as those
typically experienced during immune system attack. In non-infectious microbes such as Bacillus subtilis,
NO likely warns of increasing concentrations of nitrosative species produced by soil denitrifiers sharing
the microbe's environment. Nitric oxide would have been a likely candidate during the evolution of such a
signal as its permittivity to cell membranes makes it one of the earliest species' detectable (10).
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Nitric Oxide Synthase in Bacillus subtilis
It is perhaps because of NO's common roles as an antimicrobial and exogenous signal molecule
that the discovery of nitric oxide synthase analogs in the prokaryotic species Bacillus subtilis was
considered surprising. In 2002 the completion of the Bacillus subtilis genome sequencing project made it
possible to perform Basic Local Alignment Search Tool (BLAST) searches on the bacterium's genome
(11), revealing a sequence homologous to mammalian NOS. The protein encoded by this gene was
isolated and shown to actively manufacture NO when given concentrations of NADPH, L-arginine, and a
mammalian reducing domain (12).
Attempts to determine the purpose of this NO production began with comparisons of Bacillus
subtilis' nitric oxide synthase enzyme (bsNOS) (Figure 1.3) and its mammalian analogs (mNOS).
Mammalian NOS enzymes are homodimeric enzymes 135-160 kDa in size, and have been classified into
three forms: endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). Inducible NOS produces high
concentrations of NO during immune system activation, while eNOS and nNOS (collectively known as
constitutive or cNOS) produce lower concentrations of NO for use as second messengers targeting
isoforms of soluble guanylyl cyclase. All three classes consist of a single polypeptide with two functional
domains. The N-terminal domain binds the redox cofactor tetrahydrobiopterin (H4B) and also secures a
cytochrome P450-like heme group containing the enzyme's reactive iron species (13, 14). The C-terminal
strand binds reducing species NADPH, and also flavin adenine dinucleotide and flavin mononucleotide
(FAD and FMN, respectively) which serve to shuttle electrons from NADPH to the iron center.
Eukaryotic NOS enzymes are dependent upon the Ca2+-sensing protein calmodulin (CaM), which upon
binding triggers a conformational change in the NOS dimer that facilitates this electron transfer. The
enzyme has no activity outside of its dimeric form, which is stabilized by a zinc-binding domain located
on the N-terminal end (13, 14). With regards to activity, mammalian NOS produces NO and citrulline
from L-arginine in the presence of CaM, H4B, and oxygen (15). One exception is seen in iNOS, which
has CaM bound permanently and is therefore perpetually active, dependent only on transcription and the
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presence of substrates. All forms of NOS have activity modulated by feedback inhibition: increasing
concentrations of NO result in lower levels of manufacture.
The bsNOS gene shares 34% overall sequence similarity with cNOS, and the protein shows 52%
structural similarity in active site regions (12). It is smaller than eukaryotic NOS by approximately 360
residues and is missing key components of the cNOS species. The dimer-stabilizing N-terminal hook is
absent, as is part of the H4B-binding domain (15), and mNOS's internal reductase domain. Consequently,
bsNOS has been shown to scavenge reductase activity from other reductase enzymes (of which there are
several in the Bacillus subtilis genome) which are not explicitly dedicated to NO production (16).
In 2005, Ivan Gusarov and Evgeny Nudler suggested that native-manufactured nitric oxide
functioned as a means of "instant adaptation" when a microbe was exposed to oxidative stress. While
exogenous NO would promote a switch to anaerobic metabolism, significantly lower levels of
endogenous NO were suggested to perform two additional functions: inhibit the formation of dangerous
oxidative chemicals, and activate the oxidative stress response enzyme superoxide dismutase A (SodA,
also known as catalase A or KatA), which actively neutralizes oxidative species.
Damage from oxidative chemicals such as hydrogen peroxide is brought about by the Fenton
reaction (Figure 1.3), a sequence of steps in which the oxidative species reacts with cytoplasmic Fe2+ to
generate OH., a radical chemical species capable of damaging DNA. However, the already low
cytoplasmic concentration of Fe2+ is rapidly consumed as this occurs, and OH. production would stop
completely without reducing activity to return the resulting Fe3+ back to Fe2+. In microbes like Bacillus
subtilis, this activity is provided by the cytoplasmic concentrations of the amino acid cystine, a thiol
species. This oxidized form of cysteine, known as cystine, must be reduced as well, and this is
accomplished by thioredoxin and its counterpart thioredoxin reductase (TrxOX and TrxRED, respectively).
Left alone, cells exposed to oxidative chemicals oxidize cytoplasmic iron to produce damaging ·OH
species, at which point cytoplasmic cystine would reduce this iron back to Fe2+ for another reaction.
Cysteine would then be actively reduced by cellular TrxOX/TrxRED, perpetuating the cycle at the expense
of cellular energy stores until cell death. Gusarov and Nudler showed that to arrest this cycle, cytoplasmic
3

NO serves to inhibit the activity of thioredoxine reductase, ultimately limiting the availability of reduced
iron with which to perpetuate the reaction. This system acts as a buffer which can provide several minutes
of protection which allows a stressed cell to activate a more elaborate transcription-based oxidative stress
response. One such condition, the activation of SodA, is also NO dependent; the enzyme is S-nitrosylated
by NO to become active, and in turn begins actively scavenging oxidative species (10).
This hypothesis was confirmed four years later, with one addition: NO is also suggested to play a
key role in antibiotic resistance. Given that the modes of activity of many bactericidal species ultimately
come down to production of oxidative species, NO's activity in minimizing oxidative damage in general
may be a subsequent function. It was known that endogenous NO concentrations were generally too low
to compete with oxidative species stoichiometrically, though it is suggested that they may still have an
impact on incoming antibiotic species. Gusarov and Nudler indicated that while this was an insufficient
function on its own, endogenous NO levels did reduce the impact of antibiotic species such as acriflavin
and pyocyanin early on by directly modifying them in addition to halting the Fenton cycle they are
designed to initiate. The combination of these two functions with NO's activation of oxidant-scavenging
SodA makes native NO concentrations an effective means of preempting, detecting, and responding to
oxidative stress levels in Bacillus subtilis, and may have many analogous defense mechanisms among
prokaryotic organisms. Other species have already been shown to employ this tool, including
Staphylococcus aureus and Bacillus anthracis. Indeed, it has been suggested that this mechanism may
open a new avenue for improving antibiotic effectiveness: by inhibiting bacterial NO synthesis, it is
possible that antibiotic and/or oxidative attack from both medical treatments and immune responses could
be bolstered (17), and given the inherent differences between mammalian and prokaryotic NOS enzymes
it is plausible that such treatments could be applied chemically with minimal effect on the host.
However, kinetics studies of bsNOS do not indicate that NO concentrations resulting from the
enzyme during normal conditions would be sufficient to provide any stoichiometrically relevant level of
protection against molecules either oxidative or antibiotic. The rate of dissociation of the Fe(III)-NO
complex (the releasing step for NO) is between 10 and 20 times slower than mNOS, and establishes a
4

limit for how quickly the enzyme can manufacture NO; bsNOS ultimately generates different N-oxides if
the rate of Fe(III)-NO complex formation significantly exceeds its rate of dissociation (12). Combined
with NO's particularly short half life in biological solutions, this characteristic makes the possibility of
bsNOS single-handedly maintaining levels stoichiometrically comparable to sudden oxidative stress
unlikely, and so much of the direct neutralization behavior observed may be provided by exogenous
rather than endogenous sources.
Given that bsNOS is most comparable in activity to eukaryotic cNOS isoforms, it is possible that
native NO production in Bacillus subtilis and other prokaryotic species is used for chemical signaling.
Further, given bsNOS's low output it is likely that the message it is sending is not intended to be
effectively transmitted during oxidative attack at all as it would be immediately swamped by high levels
of exogenous NO. However, the typical receptor of eukaryotic NO signals -- guanylyl cyclase -- is not
present in the Bacillus subtilis genome, indicating that if NO's function is as a second messenger, some
other receptor(s) must be present (12).

Interest in Bacillus subtilis Nitric Oxide Activity
Interest in characterizing this function in Bacillus subtilis originates from the species' status as a
model bacterium. It is a common non-pathogenic, gram-positive soil bacterium, and has been studied and
characterized intensely; to date, its genome coding roughly 4100 genes has been mapped (18). Further, it
is cultured and handled easily, and is of close evolutionary relationship to species such as Staphylococcus
aureus, a pathogen of interest in recent years after the emergence of multiple-resistant strains (19). It is
hoped that advances in our understanding of this species can be applied across several cell lines,
potentially toward the establishment of new treatment options for infection.
Previous work used chemical inhibition of bsNOS with aminoguanidine to show that inhibition of
NO signaling during logarithmic growth (and without significant oxidative stress) resulted in the downregulation of an MreB-like protein, a nucleoside diphosphate kinase, and a phage shock protein (20).
While to date these findings have not pinpointed the nature and function of the pathways involved with
5

NO, they do indicate that some form of signal transduction may be operating outside of oxidative stress
conditions. Our work attempts to supplement this data by producing a genetic knockout of bsNOS and
comparing the resulting difference in protein inventories using two-dimensional gel electrophoresis. This
should confirm that differences observed that are not a direct result of chemical treatment but of the
absence of a native NO signal.

Intended Study
To achieve this, a plasmid was designed (arbitrarily designated pUC19∆bsNOS) which contained
a gene coding kanamycin (KAN) resistance (~1 kbp in length) inserted into the middle of the bsNOS
coding gene (Figure 1.5). To construct this plasmid, the sequence of bsNOS was selectively amplified in
two halves (5' and 3') using the polymerase chain reaction (PCR). By designing custom primers it was
possible to impart digestion sites at both ends of each fragment, allowing them to be selectively cut and
ligated to desired sequence fragments simply by matching digestion sites during ligation procedures. The
gene for kanamycin resistance was digested out of the plasmid p34S with xbaI, and the vector species
used was made from a pUC19 plasmid linearized with kpnI and pstI enzymes. The use of a plasmid made
possible the amplification of this DNA stock by transforming it into competent DH5α cells via heat shock
and then growing colonies selected for kanamycin resistance. The desired plasmid was then collected
using mini-prep.
The sequence to be inserted (the bsNOS sequence with the inserted KAN domain) was amplified
out of the pUC19∆bsNOS plasmid using PCR and then inserted into competent wild-type Bacillus subtilis
cells using electroporation, a method for generating pores in cell membranes via electrical field in order to
insert otherwise membrane-impermeable molecules (21). Following electroporation, B. sub cells are
incubated in LB broth and then grown on kanamycin-laced plates in order to select for colonies with
successfully incorporated inserts.
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Ideally, cells dividing in the presence of added DNA incorporated the insert by double
recombination. In the process of replicating genomic DNA, these cells enzymatically separated the two
DNA strands as well as the added DNA insert, and with its two ends matching the sequence of bsNOS the
insert was able to match up with its compliment in the genome and allow the formation of a Holliday
junction. From here, there were two possibilities: either the Holliday junction could twist to allow one
strand with the insert to recombine with one strand of the wild-type genome (single recombination), or it
could twist to combine two DNA strands containing the desired insert (double recombination). The latter
of these two events should have yielded cells with a full interruption of the bsNOS gene (∆bsNOS);
having both copies of the gene interrupted with the gene for KAN resistance, it would now be impossible
for the bacterium to manufacture functional bsNOS and, subsequently, NO. This can be confirmed using
PCR to amplify the entire insert sequence and then observing them in an agarose gel. The presence of
bands at ~1 kbp and ~2 kbp indicated a single recombination as both a wild type and an insert strand of
DNA were present, but the presence of a single ~2 kbp strand would have indicated that all present copies
of the gene had received an insert and had thus undergone double recombination. With a suitable
knockout colony chosen, it will then be possible to generate 2-dimensional gel electrophoresis images for
statistical comparison with chemically-inhibited wild-type Bacillus subtilis gels.
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Figure 1.1. Comparison of Mammalian nNOS and bsNOS. (A) Mammalian neuronal nitric oxide
synthase (nNOS) in its dimeric form, complexed with N~5~-(2-(methylsulfanyl)ethanimidooyl)-Lornithine (22).(PDB code 3JT3) (B) Bacillus subtilis nitric oxide synthase (bsNOS) with heme groups
bound (PDB code 2FBZ ) (23).
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Figure 1.2. Electron Micrograph Image of Bacillus subtilis Cells (24).

9

Figure 1.3. Nitric Oxide Interaction with Fenton Reaction, where KatA indicates superoxide
reductase A (SodA), and Thioredoxin(OX) indicates oxidized thioredoxin, which is inactive until reduced
by thioredoxin reductase. Green arrows indicate activation pathways,while red indicates inhibition.
Adapted from Gusarov and Nudler, Figure 5 (10).
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Figure 1.4. pUC19ΔbsNOS Plasmid Map with approximate fragment sizes and relevant restriction
sites.
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Chapter 2: Methods
Cell Cultures
Bacillus subtilis cell stocks were frozen for long-term storage at -80 °C, and stock cultures were
grown by collecting shavings of the frozen pellets with a 1 mL micropipette tip and immersing them in 50
mL sterile Luria-Bertani (LB) broth. Cultures were grown in loosely capped sterile 250 mL polycarbonate
Erlenmyer flasks and incubated at 37 °C with vigorous shaking (100-160 rpm) for at least 10 hours prior
to use. Growth in a single flask was not allowed to proceed for more than 24 hours in order to limit
stresses from nutrient exhaustion or increasing waste concentrations; prior to this time a 1:100 dilution
with fresh broth was performed in a new sterile flask. Cultures were not passaged more than four times.
Competent Bacillus subtilis cultures were produced for electroporation procedures using fresh,
750 µL stocks of cells frozen once at -80 °C. Stocks were thawed on wet ice for 10 minutes and diluted
1:200 in sterile LB broth in a loosely capped conical tube, then incubated overnight with shaking at
37 °C. The resulting stock broth was then diluted 1:20 in sterile LB then incubated at 37°C with shaking,
with optical density readings taken every 30 minutes. Once stocks had reached approximately 0.600
OD(595nm) (~3 hr), they were centrifuged at 4,400 rpm for 2 minutes to pellet and the LB broth was
decanted using an aspirator. Pellets were washed three times with deionized water (1/3 the volume of the
decanted broth), then twice more with the same volume of sterile 10% glycerol in deionized water. Pellets
were then resuspended in sterile 10% glycerol solution (1:40 wash volumes) and diluted with an equal
volume of deionized water to give a suspension in 5% glycerol. Stock was then divided up into 50 µL
aliquots and frozen on dry ice, then stored at -80°C until used.
Competent Escheria coli DH5α stocks were purchased from Invitrogen (Catalog #18258-012)
and stored at -80°C. Stocks were thawed, divided into 15µL aliquots, and refrozen on dry ice and stored at
-80°C.
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Transformation
E. coli DH5α aliquots were removed from -80°C freezer and thawed on ice for 10 minutes, then
plasmid samples were added to give 25-50 ng/µL plasmid in each solution. Samples were then mixed by
tapping and incubated on ice for 20 minutes. Next, samples were heat shocked for 1 minute in a 42°C
water bath and rescued by diluting 1:30 in sterile Super Optimal Broth (S.O.C) (VWR Direct, Catalog #
101446-764) and incubating 2 hours at 37°C with shaking.
Bacillus subtilis 168 aliquots were removed from -80°C storage and thawed on ice for 10
minutes, and then plasmid samples were added to give 25-50 ng/µL plasmid concentrations in each
solution. Samples were mixed by tapping and electroporated at settings known to be effective with
Bacillus subtilis from previous works (25) (25 mF, 200W and 2.5 kV), then rescued in 1:10 dilutions of
S.O.C broth incubated 4 hours at 37°C with shaking.
Rescued stocks were removed from incubation and 50-200 µL of each were used to inoculate
appropriate antibiotic plates. For lower-yield plasmids (modified pUC19 vectors or ligation samples in
particular) stocks were then centrifuged at 13,200 rpm for 1 minute to pellet the cells, then 50-80% of
remaining broth was removed and the pellets were resuspended via pipetting. The resulting concentrated
suspensions (100-200 µL) were then plated onto appropriate antibiotic plates.

Antibiotic Selection
Selection was performed on 1% LB-agar plates containing 50-100 µg/mL kanamycin (KAN),
ampicillin (AMP), or both. Plates were produced in batches using roughly 25 mL of the broth-agar
mixture per plate, and prior to use this broth-agar solution was autoclaved at 125°C for 15 minutes (not
including heating/cooling time). The solution was allowed to cool to ~65°C based on touch, at which
point appropriate volumes of antibiotics were added and mixed by gentle swirling. Plates were then
poured by hand and allowed to cool and solidify on the bench top covered at room temperature (~15 min)
before being stored at 4°C. Plates were used within 1 week of pouring at all times to avoid antibiotic
degradation.
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Cell cultures to be plated were added to the top of solidified plates in volumes of between 100
and 250 µL and were spread using sterile technique. Plates were then incubated overnight at 37°C.
Following incubation, colonies were picked from plates by scraping with sterile pipette tips and briefly
immersing and pumping them in sterile LB broth laced with antibiotic concentrations equal to those of the
corresponding plate. These broth solutions were incubated overnight at 37°C with shaking. Broth volumes
of 50 mL were inoculated in order to maximize miniprep yields.

Blue/White Screening
Blue/white screening was used to select colonies for the pCR 2.1 TOPO plasmids containing the
two bsNOS fragments. Plates for this selection were poured identically to 100 µg/mL ampicillin plates
with the exception that following sterilization 0.05% 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
(x-gal) and 0.005% Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added. Colonies growing with a
blue coloration were expected to have taken in a plasmid without an insert and were not selected for
further study. Selected colonies were then amplified in LB broth containing 100 µg/mL ampicillin and
kanamycin and incubated at 37°C overnight.

Plasmid Isolation
Plasmids were isolated using E. Z. N. A. Plasmid Mini Kit I (D6942-02, 200 preps) according to
the manufacturer’s standard protocol, including two washes with DNA wash buffer. Stock culture
volumes processed were increased to between 25 and 50 mL each (as opposed to the kit’s recommended
1-5 mL) to increase yield at the expense of efficiency; doing so showed total plasmid yields to increase up
to 20 fold for some plasmids. Additionally, once plasmid samples were loaded onto the microfuge
columns they were allowed to sit 5 minutes prior to centrifugation.

14

Separation of Plasmid Fragments
Electrophoresis was performed on 100mL, 1% agarose gels containing 1.5 µM ethidium bromide.
A stock solution of 50X TAE buffer (2 M Tris, 1 M acetic acid, 0.05 M EDTA, pH 8.0) was diluted to
1X. Agar-agar was added (1 g) to 100 mL of 1X TAE and then dissolved using a microwave with
periodic stirring. The clear solution was then allowed to cool to 65°C, and then 6 µL of 10 mg/mL
ethidium bromide was added and mixed by stirring. The solution was allowed to cool to 55°C and then
poured into a horizontal gel caster (BioRad Wide-Mini Sub Cell, No. 18S/7864) to solidify at room
temperature for one hour. The gel was removed from the caster, placed into a horizontal gel box, and
immersed in 1X TAE buffer. Samples without included loading dyes (ladders and PCR mixtures) were
diluted to 80% in 5X loading dye (0.015% bromophenol blue, 40% [w/v] glycerol in deionized water) and
added to gel wells by micropipette. Gels were then run at 80 V for up to 1.5 hours and quickly placed in a
UV light box (UVP BioDoc-It Imaging System) for imaging. Gels from which samples were to be
extracted had desired bands removed using a clean razor blade and then stored in a clear 1.5 mL
microfuge tube for extraction.

Restriction of Plasmid DNA
All digested samples were digested with one or more of the restriction enzymes XbaI, KpnI, or
PstI. Mixtures consisted of 0.05 to 0.2 µg/µL of DNA or plasmid sample, depending on the purpose of the
gel; higher DNA concentrations were used for digestions intended for excision and extraction of bands
after electrophoresis, while mapping digestions and others in which no collection would be used were
given lower concentrations of DNA. Additional components of digestion mixtures included 0.04 u/µL
each of appropriate restriction enzymes, 0.1 mg/mL sterile bovine serum albumin (BSA), 1X multicore
buffer solution, and deionized water. Digestion mixtures were incubated at 37°C for between 1 and 4
hours, and were immediately mixed with loading dye and resolved through electrophoresis. Gels were
imaged using a UV light box, and those with bands intended for extraction were excised.
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DNA and Plasmid Ligations
Ligations were performed using vector/insert ratios specific to each step, which were determined
by trial and error. DNA fragment solutions were combined and mixed by gentle tapping, and were heated
to 50°C on a heat block for 5 minutes and then removed from heat and incubated on ice for 20 minutes to
allow digested ends to combine. Next, 0.3 u/µL DNA ligase, 1X ligase buffer, and deionized water were
added to volume, and the solution was left at room temperature for 1 hour and then incubated for between
24 and 72 hours at 4°C. Prior to transformation, ligase was deactivated by heating ligation samples to
70°C for 5 minutes.

Purification of DNA Fragments from Agarose Gels
Excised gel bands were extracted using the QIAquick Gel Extraction Kit (Quiagen, Cat. # 28704)
with a few modifications to the kits standard protocol. Gel fractions were massed and then dissolved in
QG buffer at volumes of 2 µL/mg of gel (as opposed to the 3 µL/mg in the kit protocol), then incubated at
50°C for 10 minutes with periodic vortexing. Next, isopropanol was added at 1/3 the added volume of QG
buffer and mixed by inversion. Samples were then transferred into microfuge columns and allowed to sit
for five minutes before being centrifuged, washed, and eluted according to the official protocol.

Polymerase Chain Reaction
The sequence of the gene coding for Bacillus subtilis’ NOS enzyme was obtained from the
National Center for Biotechnology Information (NCBI) website (26) and was divided roughly in half: the
first 500 bp were chosen as the 5’ end of the gene, and the remaining 562 bp were chosen as the 3’ end.
Primers were chosen to compliment the first ~35 base pairs of each half in both directions (5’ to 3’ and 3’
to 5’) as well as desired restriction sites and are identified as 5F (5’ Forward; sequence
gggggggtaccatggaagaaaaagaaatactctgga), 5R (5’ Reverse; sequence
ggggtctagaaaatccgttcgctctccgcgccagc), 3F (3’ Forward; sequence ggggtctagatgacctgctgccgctcatttttcgc),
and 3R (3’ Reverse; sequence ggggctgcagttactcataaggcttatcttgataa). Primer 5F complimented the
16

sequence for a KpnI restriction site from the 5’ end of the bsNOS gene, and the 3R primer complimented
the sequence for a PstI restriction site from the 3’ end. Both the 5R and 3F primers complimented the
sequence for an XbaI restriction site from the 3’ and 5’ ends of their respective halves. These four primer
sequences were purchased from Eurofins MWG Operon and were mixed with deionized water to give a
100 µM solution of each, which were divided into 20 µL aliquots and stored at -20°C.
The PCR solution was mixed to contain 50% by volume of the GoTaq Green Mastermix
polymerase solution (Promega Cat. # M7122), 42 ng of the isolated B.sub 168 DNA, and 10 µM
concentrations of each desired primer. The mixture was then diluted to volume with deionized water and
placed in a thermocycler. The thermocycler program was set for an initial temperature of 94°C for two
minutes, followed by 30 cycles of 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute,
before remaining at the annealing temperature of 72°C for 7 minutes and then being cooled to 4°C until
removal. PCR samples were then stored at -20°C.

Quantification of DNA Samples
Measurements of isolated DNA or plasmid sample concentrations were performed using 1µL of
the measured sample on an ND-1000 spectrophotometer (nanodrop). After initialization with water
appropriate solvents were used to zero the device; for plasmid samples isolated using the E.Z.N.A
miniprep kit, 1 µL of the kit’s elution buffer was used. For plasmid or DNA samples extracted from an
electrophoresis gel using the QIAQuick gel extraction kit, 1 µL of the kit’s elution buffer was used. DNA
concentrations were recorded as well the ratio of absorbance at 260nm and 280nm. Given the tendency of
DNA to absorb at 260 and proteins to absorb at 280nm, a higher value for the ratio of absorbance at these
two wavelengths (260/280) indicates a solution with fewer protein contaminants. Samples with 260/280
ratios of 2.0 to 1.6 were considered clean enough for use; others were discarded.

Bacterial gDNA Isolation by Isopropanol Precipitation
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Stock cultures of Bacillus subtilis were grown to OD(595nm) = 0.600 and centrifuged at 13,200 rpm
for 2 minutes at room temperature to pellet the cells, and the supernatant broth was decanted using a
micropipette and the tube drained. Pellets were resuspended in sterile Tris-EDTA buffer (TE; 10 mM
Tris, 1 mM EDTA, pH brought to 8.0 using 1M HCl) with 0.6% by volume of sodium dodecyl sulfate
(SDS) and 120 µg/mL proteinase K. The solution was mixed and allowed to incubate for 1 hour at 37°C.
Next, an equal volume of a 1:1 mixture of phenol and chloroform was added and inverted until
phases were mixed, and the vial was centrifuged at 13,200 rpm for 2 minutes at room temperature and the
top aqueous layer was transferred into a new container. An equal volume of 1:1 phenol-chloroform was
added and again mixed via inversion until the phases had mixed, and the vial was again centrifuged. The
aqueous phase was transferred into a clean tube and 0.6 volumes of isopropanol was added and mixed by
inversion until a DNA precipitate formed. The vial was centrifuged at 13,200 rpm to pellet the DNA
precipitate and the supernatant was decanted. The DNA pellet was then washed with 70% ethanol,
centrifuged to re-pellet the precipitate, decanted, and resuspended in sterile TE buffer (pH 8.0). DNA
stocks were then stored at -20°C.

Production of 5’ and 3’ bsNOS DNA Fragments
A starter culture of Bacillus subtilis was grown overnight and then the genome was isolated by
isopropanol precipitation. Next, PCR was performed for both the 5’ and 3’ fragments of the bsNOS gene.
For the 5’ sample, 5F and 5R primers were added. For the 3’ sample, 3F and 3R primers were added. The
PCR mixture was then cleaned using electrophoresis on a 1% agarose gel with 100 bp and 1 kb ladders
added as controls and imaged. Bands identified at 500 bp (5’ fragment) and 600 bp (3’ fragment) were
excised and extracted. A diagram depicting the PCR primer setup and amplification products is shown in
Figure 2.1.
Amplification and digestion of bsNOS DNA fragments was achieved using a pCR 2.1 TOPO
plasmid kit, with 1:8 volumes each of plasmid, DNA, and salt solutions added and diluted with deionized
water. These samples were incubated 30 minutes at room temperature and then transformed into DH5α
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stocks and selected using 100µg/mL ampicillin and kanamycin blue/white plates. White colonies were
amplified in 50 mL LB with 100 ng/µL ampicillin and kanamycin and incubated overnight at 37°C with
vigorous shaking. Plasmids were isolated by miniprep and resulting plasmid concentrations were
identified using nanodrop. Stocks of pCR TOPO plasmids with the 5’ or 3’ insert were kept for future
transformations.
DNA inserts within 5’ TOPO plasmids were released by digestion using XbaI and KpnI digestive
enzymes, while 3’ TOPO plasmids were digested with XbaI and PstI. The resulting digests were cleaned
using electrophoresis and the resulting 500 and 600 bp bands (5’ and 3’ samples, respectively) were
excised, extracted, and stored at -20°C.

Production of p34S KAN Insert
The p34S plasmid coding for kanamycin resistance was received from Dr. Andre Hudson’s
inventory stock. Cell culture shavings from this strain were introduced to a 50 mL volume of sterile LB
broth using a pipette tip and incubated with shaking at 37°C overnight. Next, sterile streaking technique
was used to plate the culture on an LB-agar plate with 50 µg/mL kanamycin sulfate, and this plate was
incubated at 37°C overnight. After incubation, colonies were taken from the kanamycin plate using sterile
technique and introduced to 15 mL solutions of sterile LB broth laced with 50 µg/mL kanamycin sulfate
and incubated at 37°C with shaking overnight. The following day 14 mL of this culture was transferred to
a 15 mL conical tube and centrifuged to pellet the cells. The broth was decanted and disposed of,
plasmids were extracted from cell pellets using miniprep, and the resulting plasmid solution was stored at
-20°C.
The p34S plasmid was amplified by transformation into DH5α, followed by selection on a
100ng/µL kanamycin plate and amplification in 50 mL of 100ng/µL kanamycin LB broth. Plasmids were
isolated using miniprep and stored at -20°C.
To extract the KAN resistance gene insert, the p34S plasmid was digested with XbaI for 2 hours
and then run on a 1% agarose electrophoresis gel using 2 µg undigested p34S plasmid, along with 100 bp,
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and 1 kbp VWR DNA ladders as controls. The gel was then imaged and the band corresponding to ~1 kbp
fragment size was excised, extracted, and stored at -20°C.

Production of pUC19 Vector Fragment
A solution of pUC19 plasmid received with DH5α stock cultures (Invitrogen, ~ 10 pg/µL) was
used to transform a DH5α aliquot, and was selected on 100 ng/µL ampicillin plates. Amplification was
done in 50 mL of LB with 100 ng/µL ampicillin. Plasmids were isolated using miniprep and stored at 20°C. The pUC19 stock was then digested with KpnI + PstI for 2 hours at 37°C in a water bath and then
run on a 1% agarose electrophoresis gel using 2 µg undigested pUC19 plasmid, 100 bp, and 1 kbp ladders
as standards. The gel was then imaged and the ~2.7 kbp band was excised, extracted, and stored at -20°C.

Production of pNOS20 Phase I Plasmid
The phase I plasmid, pNOS20, was created by ligating together the pUC19 vector fragment and
the 5’ and 3’ bsNOS fragments in a 1:10:10 ratio, respectively (Dr. Andre Hudson). The ligation
procedure was followed and the mixture incubated for 72 hours, deactivated, and then transformed into a
DH5α aliquot and selected using 100 ng/µL AMP plates. Resulting colonies were amplified using 50 mL
of LB broth with 100 ng/µL AMP and incubated overnight. Samples were then miniprepped,
concentrations were measured by A260/A280 using a Nanodrop spectrophotometer, and the plasmid was
map digested with KpnI + XbaI and PstI + XbaI to observe the presence of 5’, 3’, and pUC19 vector
fragments. Plasmid stock was stored at -20°C.

Production of pUC19∆bsNOS Phase II Plasmid
The phase II plasmid, pUC19∆bsNOS, was created by first linearizing pNOS20 with XbaI and
then ligating it together with the digested p34S KAN insert at a 1:10 ratio, respectively. The ligation
procedure was followed and incubated at 4°C for 24 hours, deactivated, and then transformed into a
DH5α aliquot and selected for using 100 ng/µL AMP + KAN plates. Resulting colonies were amplified
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using 50 mL LB broth with 100 ng/µL AMP + KAN incubated overnight. Plasmids were extracted using
a miniprep kit and concentrations were measured by UV absorbance on a Nanodrop spectrophotometer,
and the plasmid was map digested with PstI + KpnI to observe the presence of 5’, 3’, KAN insert, and
pUC19 vector fragments. Plasmid stock was stored at -20°C.
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Figure 2.1. Schematic of PCR Amplification of bsNOS Gene from genomic DNA to give 5' and 3'
half-fragments of the bsNOS gene with respective restriction sites. Primers are shown as red arrows,
bsNOS-coding DNA is shown in blue, restriction-site DNA is yellow, and non-bsNOS coding DNA is
shown in gray.
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Figure 2.2. Schematic of pUC19ΔbsNOS Production from starting components to insert sequence.
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Chapter 3: Results
Following the isolation of Bacillus subtilis 168's genomic DNA, ~15 ng of DNA was loaded into
PCR mixtures for 5’ (500 bp) and 3' (600 bp) fragments. The gene fragments were amplified with custom
primers and separated using gel electrophoresis, and the resulting gel is shown in Figure 3.1. All six
bands were excised and extracted separately to give different undigested 5' and 3' DNA samples. The
sizes of these bands with respect to each other and to the DNA ladders suggest that the amplification was
successful, though the different relative intensities of these bands may indicate slight differences in the
reaction’s efficiency or more likely may simply be the result of shorter chain lengths containing fewer
numbers of ethidium bromide-binding nucleotides.
After extracting these bands, both 5' and 3' fragment stocks were ligated into pCR TOPO 2.1 and
the resulting plasmid was used to transform cultures of Escheria coli strain DH5α, selected for using
ampicillin and kanamycin at 50 µg/mL. After amplifying and miniprepping the colonies, 12 µg of the 5’
and 3’ TOPO plasmids were digested with KpnI and PstI, respectively, along with XbaI in 50 µL
mixtures. The digestion mix was then run through an electrophoresis gel, pictured in Figure 3.2, and the
bands corresponding to the 5' and 3' inserts (500 and 600 bp, respectively) were excised. Fragments cut
from pCR TOPO plasmids are considered fully digested as removal from the plasmid necessitates
digestion, and so the 5' and 3' bsNOS fragments were now extracted and stored prior to ligation.
The vector plasmid pUC19 was now amplified through DH5α and selected for using 50 µg/mL
ampicillin plates. After growth and isolation, 200 ng of each were added to a 20 µL digestion mixture
containing restriction enzymes KpnI and PstI. The mixtures were then incubated and run through an
electrophoresis gel, pictured in Figure 3.3. Some additional fragments were seen in undigested plasmid
samples, though these were likely a consequence of supercoiling or linearization due to random
degradation in the undigested plasmids. Excised bands from pUC19 and p34S plasmids were extracted to
give solutions of digested pUC19 and KAN fragments, respectively.
A ligation mixture was produced containing a 1:10 ratio of digested pUC19 vector to digested 5'
and 3' inserts and incubated for 48 hours at 4°C. Following ligation the mixture was deactivated by
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incubation at 70°C for five minutes and then was used to transform samples of DH5α. These samples
were plated on agar with 50 µg/mL ampicillin and then nine colonies were selected for amplification,
after which plasmid content was isolated via miniprep as pNOS20 candidate samples (A through I).
To test for the desired inserts a mapping digest was performed in which roughly 0.1 µg of each
plasmid sample was added to a 10 µL digestion mixture containing the restriction enzymes XbaI and KpnI
in order to cut out the 5' fragment from each plasmid. After incubation these digestion mixtures were
loaded into a 30-lane agarose gel to check for the desired band patterns. The desired plasmid should give
a 500 bp fragment under these digestion conditions, and all but one sample (sample D) showed bands of
this size, as seen in Figure 3.4. All samples with the exception of D were then tested for a 3' fragment
insert in the same fashion; roughly 0.1 µg of each was digested in a 10 µL digestion mixture containing
XbaI and PstI restriction enzymes. The correct plasmid ligation should give a 600 bp fragment under
these conditions. An agarose gel was poured and the samples were run through it to check for the desired
fragment; the resulting gel is shown in Figure 3.5. All samples were shown to have the 3' insert as well,
and were thus confirmed to be the desired pNOS20 plasmid product.
Three of the confirmed pNOS20 samples (B, C, and F) were selected to be linearized with XbaI.
Three 20 µL digestion mixtures were prepared containing 4 µg of each respective plasmid sample and the
XbaI restriction enzyme. An additional digest was performed using XbaI on a sample containing p34S
plasmid in order to provide an additional control sample as well as a fresh sample of the digested KAN
fragment for extraction. After incubation the samples were run through an agarose gel with 1kbp and
100bp VWR ladders as controls. This gel is shown in Figure 3.6. The digested bands from each sample as
well as the 1.1 kbp p34S digest band were excised and extracted to give solutions of linearized pNOS20
as well as the digested KAN gene, respectively.
Following excision a ligation mixture was produced containing a ratio of 1:10 pNOS20 to KAN
insert, with a total of approximately 100 ng of DNA in 25 µL ligation mixtures. The ligation mixture was
incubated 24 hours and then deactivated before being used to transform samples of DH5α. After rescue,
transformed samples were grown on plates laced with 50 µg/mL kanamycin and ampicillin and four
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colonies were selected for amplification (A, B, C, and D). After amplification, plasmids were extracted
via miniprep to yield solutions of pUC19∆bsNOS candidates. These plasmid solutions were then
digestion mapped to test for the presence of 5', 3', and KAN inserts. To do this, 20µL digestion mixtures
were made containing ~0.2 µg of plasmid along with PstI and KpnI restriction enzymes. Given the
presence of all three restriction sites at the ends of the KAN insert, this mixture would be expected to
liberate all four fragments from the plasmid, yielding a fragmentation pattern with bands at 500 bp, 600
bp, 1.1 kbp, and ~2.7 kbp. Following incubation the digestion mixtures were run through a 15-well
agarose gel alongside undigested samples and a 1 kbp and ladder as controls. This gel is shown in Figure
3.7. Based on the resulting digestion patterns, all five selected colonies yielded pUC19∆bsNOS plasmids.
With digestion mapping results which suggested that the goal of generating pUC19∆bsNOS had
been accomplished, the final confirmation needed was to sequence the generated plasmid's insert through
the University of Rochester's sequencing lab (27). While the total pUC19∆bsNOS plasmid was available,
the pNOS20 plasmid was submitted for sequencing as the KAN gene sequence is already known and
would have doubled the required sequence to be amplified. As such, samples from pNOS20 candidate F
were produced and submitted to the University of Rochester to be sequenced. When run through the
National Center for Biotechnology Information's online BLAST, the sequence returned appears identical
to that of bsNOS: among the four samples submitted, total sequence similarity and maximum alignment
scores average out to be 97.8% and 1810, respectively. The minimum sequence similarity seen from any
of the samples was 97%, and the lowest maximum alignment score was 1753. Overall, it appears
definitive that the pNOS20 sample selected was correctly identified, and from this it can be extrapolated
that its ligation with digested KAN should have formed the pUC19∆bsNOS plasmid, again confirming
mapping digest data (11). An example of the sequence alignment data given by BLAST search is shown
in Figure 3.8.
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Figure 3.1. PCR-Amplified bsNOS Fragment Gel, showing 5' and 3' fragments resolved on an
electrophoresis gel. The 5' fragments were all excised to give 5' fragment samples, and the 3' fragment
bands were all excised to give 3' fragment samples. Lanes 1 and 15 contain a mixture of VWR 1kb and
100 bp ladders; lanes 3, 5, and 7contain 5' PCR mixtures, and lanes 9, 11, and 13 contain 3' PCR
mixtures.
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Figure 3.2. 5' and 3' TOPO Plasmid Digests, before and after their digestion. The 500 bp fragment
from the 5' TOPO digestion was excised for extraction to give the digested 5' fragment solution. The 600
bp fragment from the 3' TOPO digestion was excised for extraction to give the digested 3' fragment
solution. Lanes 1 and 2 contain VWR 1kbp and 100 bp ladders, respectively. Lane 3 contains undigested
5' pCR TOPO plasmid, and lane 4 contains digested 5' pCR TOPO plasmid. Lane 5 contains undigested 3'
pCR TOPO plasmid, and lane 6 contains digested 3' pCR TOPO plasmid.
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Figure 3.3. Digestion of pUC19 and p34S plasmids. For pUC19 the second fragment removed
through digestion is too small (<100 bp) to be identified on a 1% gel with given concentrations of
ethidium bromide; thus the 2.6 kbp band was the only one observed after digestion and was subsequently
excised for extraction. The p34S digestion yielded two fragments: one at ~1 kbp and another at ~2.5 kbp.
The 1 kbp fragment correlated with the desired KAN resistance gene, and so was excised for extraction.
Undigested plasmid sizes (lanes 3 and 5) were measured from the faint lines seen above the larger spots
as the larger spots likely represent plasmid sizes after supercoiling and therefore do not accurately
represent the undigested plasmid's size. Lanes 1 and 2 contain VWR 1kbp and 100 bp ladders,
respectively. Lanes 3 and 5 contain undigested pUC19 and p34S plasmids, respectively, while lanes 4 and
6 contain digested pUC19 and p34S, respectively.
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Figure 3.4. 5' Digestion Mapping Gel of pNOS20 ligation samples to test samples A through I for the
presence of the 5' bsNOS fragment insert. Samples both digested and undigested were run, with 1 kbp and
100 bp ladders for control. All but sample D exhibited the desired 500 bp fragment. Lanes 1 and 22
contain a VWR 1 kbp ladder, and lanes 2 and 21 contain a VWR 100 bp ladder. Odd numbered lanes
from 3 to 19 contain undigested samples A through I (left to right), and even numbered lanes from 4 to 20
contain digested samples A through I (left to right).
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Figure 3.5. 3' Digestion Mapping Gel of pNOS20. Testing of samples A through I (sans D) for the
presence of the 3' bsNOS fragment insert. All samples exhibited the desired 600 bp fragment. Lanes 1 and
2 contain VWR 1 kbp and 100 bp ladders for control. Lanes 3 through 10 contain digested samples A
through I (left to right, sample D not processed).
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Figure 3.6. pNOS20 Linearization Gel. Ligation samples B, C, and F linearized with XbaI. Undigested
plasmids traveled slightly further due to supercoiling and so comparisons between digested and
undigested plasmid confirm that digestion did occur in each case. Bands of linearized samples were
excised for extraction. Plasmid p34S was also digested with XbaI and run alongside an undigested
control; the ~1 kbp fragment band of this digest was extracted as a source of fresh digested KAN gene
sequence. Lanes 1 and 2 contain VWR 1 kbp and 100 bp ladders, respectively. Lanes 3, 5, and 7 contain
undigested plasmid samples B, C, and F, respectively, and lanes 4, 6, and 8 contain their digested
counterparts, respectively. Lane 9 contains undigested p34S (after supercoiling), and lane 10 contains
digested p34S.
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Figure 3.7. Digestion Mapping Gel of pUC19ΔbsNOS Candidates. Samples A-D were digested with
PstI and KpnI, and were run alongside undigested samples. All four samples appear to include all four
component fragments, suggesting that the pUC19∆bsNOS plasmid has been successfully constructed in
each case. Lane 1 contains a VWR 1 kbp ladder. Lanes 2, 4, 6, and 8 contain undigested samples A
through D (after supercoiling), and lanes 3, 5, 7, and 9 contain samples A through D after digestion.
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Figure 3.8. Sequence Alignment of the pNOS20 Insert as compared by NCBI BLAST search to the
wild-type bsNOS gene. The upper line of each row represents the plasmid sequence submitted, and the
lower sequence is taken from the bsNOS genome. Vertical lines represent identical bases, while missing
lines represent mismatches. (11).
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Chapter 4: Discussion
Based on the sequence data returned by the University of Rochester and the mapping digests
performed, it can be concluded that the pUC19∆bsNOS plasmid has been successfully constructed and
should be easily amplified and/or used for transformation of Bacillus subtilis. The use of pUC19 as a
vector makes amplification easy through transformation and selection of DH5α, though given that PCR is
to be used to generate the desired fragments from the pUC19∆bsNOS only very small concentrations of
this plasmid should be needed.
The next step in this method will be the transformation of wild-type Bacillus subtilis 168 with the
insert. Ideally, treatments should be possible simply by electroporating the entire pUC19∆bsNOS plasmid
into competent B.sub stocks, but to date this method has not worked. It is possible that even after
unraveling the extra 2.7 kbp of non-insert plasmid regions are making encounters between the insert
strand and its compliment difficult; in any case it was decided that the insert needed to be removed from
the plasmid before the transformation could work efficiently.
Removal of the insert sequence (roughly 2.1 kbp in length) was originally going to be
accomplished using the KpnI and PstI restriction sites, but the presence of both sites on either end of the
KAN gene of the p34S plasmid make it impossible to sever the insert as a whole using only the restriction
enzymes in our stock. It could be possible to remove this strand using different restriction enzymes, but
prior to this it was decided that using PCR to amplify our desired strand would be most efficient. First, it
should allow the sequence to be generated in its entirety without any additional non-coding regions of the
plasmid being brought along (as would be necessary if new restriction sites down-stream of the insert
were to be targeted). Second, the use of PCR means that very low concentrations of pUC19∆bsNOS
plasmid would be needed for a transformation procedure, and that if needed a much higher number of
insert copies could be generated than may be possible using digested and cleaned plasmid minipreps.
PCR amplification of the insert from the pUC19∆bsNOS plasmid has already been performed
and indeed has appeared successful. Bacillus subtilis colonies were seen on 40 µg/mL kanamycin plates,
and to date over a dozen colonies have been selected, grown, and their DNA isolated by isopropyl
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precipitation. Once this DNA is purified it should be possible to use PCR to amplify the insert from the
genomic DNA; a successful double-recombination should give only one band at approximately 2.1 kbp,
while a single recombination should show two bands: one at 2.1 kbp and another at 1 kbp. Unfortunately,
complications have arisen in the PCR process. For reasons yet unknown, amplification of the bsNOS site
has proven difficult.
While our described methods were (and still are) fully capable of amplifying the 5' and 3' halves
of the gene independently, the 1 kbp wild type sequence has been problematic, giving very low yields
based on band luminosity and suggesting that some variable in amplification efficiency has yet to be
identified. As of this writing all colonies isolated have been tested, but only one or two (wild-type or
treated) have shown definitive 1 kbp bands (indicating at best a single recombination product),
and none have shown the 2.1 kbp band associated with a complete insert. Given that all colonies have
been selected from kanamycin plates and that a full plasmid was not inserted it can be assumed that the
KAN gene has inserted into the genome at some locus, and it is statistically unlikely that this occurred at a
random region of the genome (although this possibility is not being ignored). Further, all colonies isolated
give strong 500 or 600 bp bands when the 5' or 3' halves are amplified, indicating that all primers are
finding targets and that the colonies isolated are all in fact Bacillus subtilis. If a complication in the PCR
procedure is preventing the 1 kbp strand from being amplified, it is very likely that the same complication
is making the 2.1 kbp insert even more difficult. Consequently, the lack of a 2.1 kbp band cannot yet be
attributed to a lack of an insert, and so these issues with PCR products must be overcome before
definitive testing of the potential knockout mutants can begin. Variables to be changed so far include
timing programs for the thermocycler used in the PCR process as well as changes in DNA or primer
concentrations.
While definitive PCR data is still lacking, the colonies themselves do appear promising. Wildtype Bacillus subtilis does not grow on kanamycin plates, and yet the treated colonies are showing up as
small, interspersed "pin-prick" colonies, a pattern typical of such transformation procedures. Additionally,
wild-type Bacillus subtilis, even when selected from culture plates, grows rapidly and with high viability;
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colonies selected can normally be incubated in LB broth overnight and consistently give turbid cultures.
Colonies selected from the kanamycin plates, however, grow very slowly, and with a roughly 70%
success rate. Incubation of selected colonies in even 10 ng/µL kanamycin (25% of the concentration used
in the selection plate) took between 48 and 72 hours to reach even low turbidity, and 30% of colonies
selected apparently fail to take hold. This low viability is likely due in part to the presence of kanamycin,
but it is also consistent with the findings of other works in which bsNOS knockouts showed lower cell
viability in the presence of antibiotics (17).
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Chapter 5: Conclusions
Current work has strongly suggested that nitric oxide is manufactured in Bacillus subtilis at levels
far below those necessary for recently observed oxidative stress mechanisms even at times of nonstressed, logarithmic growth. This may indicate a native pathway in which NO is a key signal, and to date
work is underway to identify just what this signal promotes. A simple means of identification is to inhibit
production of this molecule and observe consequent changes proteomically, and while previous work
allowed native bsNOS to be inhibited chemically it is also necessary to account for the presence of the
added inhibitory chemical species. This will be accomplished using a genetic knockout of bsNOS. An
antibiotic resistance gene inserted into the center of the bsNOS gene should inhibit the bacterium from
producing native NO, and thus any signals carried by this molecule will be silenced. With the
pUC19∆bsNOS plasmid complete, the only steps that remain in generating this knockout species include
selecting a successful knockout colony and confirming its status as a complete knockout.
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